tiprankstipranks
Trending News
More News >
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market

Inhibikase Therapeutics (IKT) Income Statement

Compare
172 Followers

Inhibikase Therapeutics Income Statement

Last quarter (Q3 2025), Inhibikase Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Inhibikase Therapeutics's net income was $-11.93M. See Inhibikase Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 260.50K$ 123.44K$ 3.10M$ 698.47K
Gross Profit
$ -26.27K$ -13.36M$ 116.72K$ -8.26M$ -195.33K
Operating Expenses
$ 28.56M$ 6.73M$ 18.25M$ 6.51M$ 2.62M
Depreciation and Amortization
$ 26.27K$ 177.40K$ 6.72K$ 14.77M$ 2.82M
EBITDA
$ -27.49M$ -19.91M$ -18.05M$ 0.00$ 0.00
Operating Income
$ -28.59M$ -20.09M$ -18.13M$ -14.77M$ -2.82M
Other Income/Expenses
$ 1.07M$ 1.06M$ 74.45K$ -19.92K$ -29.40K
Pretax Income
$ -27.52M$ -19.03M$ -18.05M$ -14.79M$ -2.85M
Net Income
$ -27.52M$ -19.03M$ -18.05M$ -14.79M$ -2.85M
Per Share Metrics
Basic EPS
$ -1.16$ -3.57$ -4.26$ -4.88$ -1.72
Diluted EPS
$ -1.16$ -3.57$ -4.26$ -4.88$ -1.72
Weighted Average Shares Outstanding
69.36M 5.33M 4.20M 3.03M 1.68M
Weighted Average Shares Outstanding (Diluted)
69.36M 5.33M 4.20M 3.03M 1.68M
Currency in USD

Inhibikase Therapeutics Earnings and Revenue History